Key result
Oral magnetoelectric neuroimmunomodulation reduces AF duration and cardiac inflammation in rats by activating vagal pathways.
Why the study?
Low-level vagus nerve stimulation offers therapeutic benefits for AF, but clinical application is limited by the need for surgical implants.
Does an orally delivered magnetoelectric neuroimmunomodulation platform reduce AF duration and cardiac inflammation in a rat AF model?
Does an orally delivered magnetoelectric neuroimmunomodulation platform reduce AF duration and cardiac inflammation in a rat AF model?
An innovative ingestible magnetoelectric platform enables noninvasive low-level vagus nerve stimulation, effectively reducing AF duration and cardiac inflammation in a preclinical model.
Answers are grounded in this paper and cite their sources.
Supports oral magnetoelectric vagal stimulation development for AF; leaves open translation from rat models to clinical use.
Atrial fibrillation (AF), the most common cardiac arrhythmia, is closely associated with autonomic imbalance and inflammation. While low‐level vagus nerve stimulation (LL‐VNS) offers therapeutic benefits, its clinical application is limited by the need for surgical implants. Here, we present a noninvasive, orally delivered magnetoelectric neuroimmunomodulation platform that targets the gut–brain–spleen–heart axis to deliver LL‐VNS for AF therapy. The platform comprises ingestible microparticles (MPs) embedding magnetostrictive Fe 3 O 4 @BaTiO 3 nanogenerators (FO@BTO NGs) within a conductive matrix of poly(3,4‐ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS), which facilitates electrical signal transmission, and dopamine–alginate, which promotes gastric adhesion via catechol‐mediated interactions. After oral gavage in a rat AF model, MPs adhere to the stomach lining and, upon alternating magnetic activation, FO@BTO NGs generate pulsed electrical currents that stimulate vagal afferent fibers. This activates brainstem autonomic circuits, enhancing parasympathetic tone and suppressing sympathetic activity. Concurrently, it engages the splenic neuroimmune circuit via the cholinergic anti‐inflammatory pathway, thereby reducing systemic inflammation. This dual neuroimmune modulation significantly shortens AF duration and mitigates cardiac inflammation and electrical remodeling. These findings establish a clinically translatable, implant‐free strategy for delivering LL‐VNS through coordinated neural and immune pathways, offering a safe and accessible alternative to implantable systems for AF management.
No takes yet. Share an insight, caveat, or question.
Mac et al. (2026) studied this question. Orally delivered magnetoelectric neuroimmunomodulation reduced atrial fibrillation duration and cardiac inflammation in rats by activating vagal and anti-inflammatory pathways.
Synapse has enriched 10 related papers. Consider them for comparative context: